Things
The Call is promoted by the University of Milan and has the objective of: • adapting and validating technologies that are currently available and in line with current legislation, for the research and development of RNA drugs; • create new tailor-made technologies that allow us to accelerate the research and development of RNA drugs and that facilitate the transition from preclinical research to the clinic with particular emphasis on the use of imaging and biomarker technologies; • develop innovative regulatory strategies.
Who is it aimed at?
The following can request the benefits referred to in this Notice: ● Micro, Small and Medium Enterprises (MSMEs) having the dimensional parameters referred to in Annex I of Regulation (EU) 2014/651 of the Commission of 17 June 2014 which declares certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty (Text with EEA relevance), including innovative start-ups and excluding sole proprietorships;● Large Enterprises (GI);● Public research bodies and institutions, including universities, and the bodies referred to in Legislative Decree no. 218/2016 (https://www.mur.gov.it/it/aree-tematiche/ricerca/il-sistema-della-ricerca/entidi -public-research);● Private Research Organizations registered in the National Research Registry;● Scientific Hospitalization and Treatment Institutes - IRCCS, which are public or private in nature;● Bodies referred to in the Third Sector Code - Legislative Decree. Legislative Decree no. 117 of 3 July 2017 and subsequent amendments
What does it predict
The project proposals must include Fundamental Research and Industrial Research activities and be consistent in terms of repercussions and impacts of the results with the research and innovation themes
